Invivyd Reports Second Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 08/10/23
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 08/03/23
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised PeopleGlobeNewsWire • 07/17/23
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19GlobeNewsWire • 06/26/23
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised PeopleGlobeNewsWire • 06/22/23
INVIVYD ALERT: Bragar Eagel & Squire, P.C. is Investigating Invivyd, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 05/27/23
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 05/04/23
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial UpdateGlobeNewsWire • 04/25/23
After Plunging -26.71% in 4 Weeks, Here's Why the Trend Might Reverse for Invivyd, Inc. (IVVD)Zacks Investment Research • 04/14/23
Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing OfficerGlobeNewsWire • 04/12/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. - IVVD; ADGIPRNewsWire • 04/03/23
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Invivyd Investors of a Lead Plaintiff Deadline of April 3, 2023PRNewsWire • 04/03/23
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD)Business Wire • 03/31/23
IVVD Investors Have Opportunity to Lead Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Securities Fraud LawsuitPRNewsWire • 03/31/23
IVVD SHAREHOLDER ALERT: Jakubowitz Law Reminds Invivyd Shareholders of a Lead Plaintiff Deadline of April 3, 2023PRNewsWire • 03/31/23
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses to Contact the FirmAccesswire • 03/30/23
Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19GlobeNewsWire • 03/30/23
IVVD LAWSUIT ALERT: Levi & Korsinsky Notifies Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlinePRNewsWire • 03/30/23
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 3, 2023 - (NASDAQ: IVVD)PRNewsWire • 03/29/23
IVVD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 3, 2023 in the Class Action Filed on Behalf of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ShareholdersPRNewsWire • 03/28/23
